Structural and Functional Properties of the Capsid Protein of Dengue and Related <i>Flavivirus</i>

• Main Authors: André F. Faustino, Ana S. Martins, Nina Karguth, Vanessa Artilheiro, Francisco J. Enguita, Joana C. Ricardo, Nuno C. Santos, Ivo C. Martins
• Format: Article
• Language: English
• Published: MDPI AG 2019-08-01
• Series: International Journal of Molecular Sciences
• Subjects: Dengue virus (DENV); capsid protein (C protein); <i>Flavivirus</i>; intrinsically disordered protein (IDP); protein–RNA interactions; protein–host lipid systems interaction; circular dichroism; time-resolved fluorescence anisotropy
• Online Access: https://www.mdpi.com/1422-0067/20/16/3870

Dengue, West Nile and Zika, closely related viruses of the Flaviviridae family, are an increasing global threat, due to the expansion of their mosquito vectors. They present a very similar viral particle with an outer lipid bilayer containing two viral proteins and, within it, the nucleocapsid core. This core is composed by the viral RNA complexed with multiple copies of the capsid protein, a crucial structural protein that mediates not only viral assembly, but also encapsidation, by interacting with host lipid systems. The capsid is a homodimeric protein that contains a disordered N-terminal region, an intermediate flexible fold section and a very stable conserved fold region. Since a better understanding of its structure can give light into its biological activity, here, first, we compared and analyzed relevant mosquito-borne <i>Flavivirus</i> capsid protein sequences and their predicted structures. Then, we studied the alternative conformations enabled by the N-terminal region. Finally, using dengue virus capsid protein as main model, we correlated the protein size, thermal stability and function with its structure/dynamics features. The findings suggest that the capsid protein interaction with host lipid systems leads to minor allosteric changes that may modulate the specific binding of the protein to the viral RNA. Such mechanism can be targeted in future drug development strategies, namely by using improved versions of pep14-23, a dengue virus capsid protein peptide inhibitor, previously developed by us. Such knowledge can yield promising advances against Zika, dengue and closely related <i>Flavivirus</i>.